What is DNA Script?
Founded in 2014, DNA Script is a pioneering life sciences technology company that has fundamentally reimagined the manufacturing of nucleic acids. By moving away from traditional, chemical-based synthesis methods, the company has introduced Enzymatic DNA Synthesis (EDS), a cleaner and more versatile alternative. This technological breakthrough is embodied in the SYNTAX System, the industry's first benchtop instrument designed to provide researchers with unprecedented autonomy and control over their experimental workflows. By enabling on-demand DNA production, DNA Script is actively reducing the latency associated with outsourced synthesis, thereby accelerating the pace of discovery in genomics, synthetic biology, and personalized medicine. The company's market position is bolstered by its ability to integrate seamlessly into existing laboratory infrastructures, providing a scalable solution for complex biological research.
How much funding has DNA Script raised?
DNA Script has raised a total of $302M across 3 funding rounds:
Series A
$13M
Series B
$89M
Series C
$200M
Series A (2017): $13M with participation from Illumina Ventures
Series B (2020): $89M led by Casdin Capital, M Ventures, Agilent Technologies, Bpifrance Large Venture Fund, Life Sciences Partners, Danaher Life Sciences, and Illumina Ventures
Series C (2021): $200M supported by Catalio Capital Management and Coatue
Key Investors in DNA Script
Catalio Capital Management
A New York-based investment firm specializing in breakthrough biomedical technology, leveraging a deep network of venture partners to support category-defining healthcare companies.
Coatue
A prominent global investment manager with a focus on both public and private equity, known for backing high-growth technology and innovation-driven enterprises.
M Ventures
The strategic corporate venture capital arm of Merck, dedicated to investing in transformational technologies that impact core business areas through active partnership and company creation.
What's next for DNA Script?
With the successful completion of its latest financing round, DNA Script is well-positioned to scale its global operations and expand the reach of its benchtop synthesis platforms. The strategic focus will likely shift toward increasing manufacturing capacity, enhancing the performance of the SYNTAX System, and broadening its commercial footprint across international markets. As the demand for rapid, reliable, and accessible DNA synthesis continues to grow within the biopharmaceutical and academic research sectors, DNA Script is poised to capitalize on its first-mover advantage in the EDS space. Future growth initiatives will likely prioritize the development of new applications for its enzymatic platform, further cementing its role as a critical infrastructure provider in the modern life sciences ecosystem.
See full DNA Script company page
